Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy. 71% achieved a >30% reduction in UP/Cr, a key indicator of kidney damage. 71% demonstrated improved or stabilized eGFR, signaling preserved...
Read More Details
Finally We wish PressBee provided you with enough information of ( Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting )
Also on site :
- Anne Burrell's Memorial Included 'Big Send-Off' of Billy Joel Karaoke With Food Network Colleagues
- Planting the seeds for remembering
- NYT Mini Crossword Answers, Hints for Saturday, June 21, 2025